According to the BC and GEA HER2 IHC diagnostic criteria, 98 (2.03%) were scored up to HER2 1+, 266 (5.50%) were scored up to but no higher than HER2 2+, and 73 cases (1.51%) were scored up to HER2 3+. This evidence concerns the gene ERBB2 and breast cancer.